$36 Million Funding Boosts Remepy's AI-Driven Parkinson's Therapy

Remepy has secured $36 million in Series A funding to advance its AI-driven therapy for Parkinson's disease, Hybridopa. The Israeli company plans to use this capital to fund a global Phase III clinical trial scheduled to begin in Q4 2026.

The financing was led by OG Venture Partners and M Ventures, the corporate strategic venture arm of Merck KGaA. Existing and new investors participated, bringing Remepy's total funding to $62 million.

Hybridopa combines pharmacological treatment with adaptive digital interventions delivered through software. This approach has generated encouraging Phase IIa clinical data showing improvements in both motor and non-motor symptoms of Parkinson's disease.